In Japan, Biocon Biologics and Sandoz have an agreement to market the biosimilar drug Humira, adalimumab

 In Japan, Biocon Biologics and Sandoz have an agreement to market the biosimilar drug Humira, adalimumab

 In Japan, Biocon Biologics and Sandoz have an agreement to market the biosimilar drug Humira, adalimumab

A biosimilar of Humira, adalimumab BS for subcutaneous injection offers a treatment for immune-related conditions such ulcerative colitis, psoriasis vulgaris, ankylosing spondylitis, rheumatoid arthritis, and Crohn's disease.

The arrangement is a calculated attempt to increase Biocon Biologics' market share in Japan, and it takes effect immediately.

The subsidiary of Biocon Ltd., Biocon Biologics Ltd. (BBL), has secured exclusive rights for the marketing, sales, and distribution of "Adalimumab BS for Subcutaneous Injection [FKB]" in Japan via a significant distribution arrangement with Sandoz.

With immediate effect, the arrangement is a calculated attempt to bolster Biocon Biologics' position in the Japanese market.

A biosimilar of Humira, adalimumab (generic name: adalimumab (genetic recombinant) for subcutaneous injection offers a treatment for immune-related conditions such rheumatoid arthritis, psoriasis vulgaris, ankylosing spondylitis, Crohn's disease, and ulcerative colitis. Does. Biosimilars are set to enter the Japanese market, potentially filling gaps in the treatment of patients with these difficult illnesses.

The market for adalimumab biosimilars is expected to grow from $613.28 million in 2022 to $3954.75 million in 2031 at a compound annual growth rate of 23.2 percent between 2023 and 2031.

This most recent event comes after Viatris' worldwide biosimilar portfolio—which includes the highly sought-after adalimumab—was acquired by Biocon Biologics. An subsidiary of Biocon Biologics Ltd. has entered into an exclusive worldwide marketing licensing deal with the drug's inventor, Fujifilm Kyowa Kirin Biologics Co. Ltd.

By December 15, 2023, Viatris will have successfully fulfilled the agreement's requirements for marketing and promotion of the biosimilar product. Viatris will, however, continue to facilitate the transition until February 15, 2024, at which point Sandoz will progressively take over complete responsibility. Adalimumab BS distribution.

A major turning point in Biocon Biologics' journey was the completion of the biosimilar business of Viatris, which it had acquired in 120 countries ahead of schedule. Biocon Biologics has a robust pipeline consisting of twenty assets in the fields of immunology, ophthalmology, cancer, and diabetology worldwide.